Related Experiment Videos
Abstract:
Anastrozole (Arimidex-Zeneca) and letrozole (Femara-Novartis) are the first selective, oral, non-steroidal aromatase inhibitors. They are licensed for the treatment of advanced breast cancer in postmenopausal women where tamoxifen or other anti-oestrogen therapy has failed. The manufacturers of both drugs claim that their products are more effective, less toxic and better tolerated than the progestogen megestrol acetate, the standard therapy in this clinical situation. We assess these claims.
Insights
Anastrozole and letrozole are new oral non-steroidal aromatase inhibitors for advanced breast cancer. This study assesses manufacturer claims of superiority over megestrol acetate in efficacy and tolerability.
Area of Science:
- Oncology
- Pharmacology
Background:
- Anastrozole and letrozole are selective, oral, non-steroidal aromatase inhibitors.
- They are approved for postmenopausal women with advanced breast cancer resistant to tamoxifen or other anti-estrogen therapies.
Purpose of the Study:
- To evaluate manufacturer claims comparing anastrozole and letrozole to megestrol acetate.
- To assess efficacy, toxicity, and tolerability of these treatments.
Main Methods:
- Comparative assessment of anastrozole and letrozole against megestrol acetate.
- Evaluation based on manufacturer claims regarding effectiveness and side effect profiles.
Main Results:
- Claims regarding superior efficacy of anastrozole and letrozole require thorough clinical assessment.
- Toxicity and tolerability profiles of the new agents are compared to the established standard.
Conclusions:
- This study critically examines the comparative advantages of anastrozole and letrozole over megestrol acetate.
- Evidence is presented to support or refute claims of improved treatment outcomes in advanced breast cancer.